Paul James
Nurse Practitioner · Lake City, SCNPI 1720629512
Payments from drug & device makers
Across 51 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$109
- Boehringer Ingelheim$103
- AstraZeneca$100
- Novo Nordisk$73
- Phathom Pharmaceuticals, Inc.$59
- Dexcom, Inc.$55
- plus $449 from 15 others
What the payments were for
- Food & beverage$948100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 6 | $109 |
| Boehringer Ingelheim | 5 | $103 |
| AstraZeneca | 6 | $100 |
| Novo Nordisk | 4 | $73 |
| Phathom Pharmaceuticals, Inc. | 4 | $59 |
| Dexcom, Inc. | 2 | $55 |
| Abbott | 3 | $49 |
| Pfizer | 2 | $44 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| Exact Sciences | 2 | $39 |
| Merck | 2 | $38 |
| Shield Therapeutics Inc | 2 | $37 |
| Bayer | 2 | $36 |
| GSK | 2 | $35 |
| Hologic Sales And Service, LLC | 1 | $26 |
| Gilead | 1 | $23 |
| Insulet Corporation | 1 | $18 |
| Novartis | 1 | $17 |
| Amgen | 1 | $17 |
| AbbVie | 1 | $17 |
| Indivior Inc. | 1 | $15 |
How this compares
$948 in reported general payments places this provider in the 75th percentile of 1,346 nurse practitioner providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 184 | $197,924 |
| OzempicSemaglutide | 42 | $59,439 |
| EntrestoSacubitril/Valsartan | 36 | $51,701 |
| TrulicityDulaglutide | 45 | $49,506 |
| EliquisApixaban | 45 | $45,256 |
| JanuviaSitagliptin Phosphate | 40 | $30,776 |
| TradjentaLinagliptin | 32 | $29,767 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 24 | $22,095 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $16,311 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $12,332 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $10,624 |
| LinzessLinaclotide | 15 | $9,145 |
| Spiriva HandihalerTiotropium Bromide | 13 | $7,239 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $7,045 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Spiriva Respimat | $103 | $256,269253 claims |
| Novo NordiskOzempic | $73 | $59,43942 claims |
| NovartisEntresto | $17 | $51,70136 claims |
| Lilly USA, LLCTrulicity | $109 | $49,50645 claims |
| PfizerEliquis | $44 | $45,25645 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta | $35 | $37,98367 claims |
| MerckJanuvia | $38 | $30,77640 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $100 | $17,37644 claims |
| AbbVieLinzess | $17 | $9,14515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,346 nurse practitioner providers in South Carolina.
Other nurse practitioner in Lake City
- Jenna DavisColumbia$202K
- David WiltGreenville$90K
- Whitney ReedCharleston$54K
- Mary JohnsonCharleston$34K
- Amanda HareCharleston$30K
- Kellie McLainCharleston$28K
- Colleen BoydSummerville$21K
- Mae BurtonGreenville$21K
- Melissa BramanteColumbia$19K
- Gail KirbyGreer$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.